Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sialanar in Pediatric Severe Sialorrhoea
NCT04873115Phase 4Unknown
- Sponsor
- Proveca
- Start
- May 2021
- Primary completion
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in sialorrhea comparing Sialanar with Placebo (2 arms). Primary endpoint: Change in Drooling Impact Scale (DIS) between baseline and D84 at 84 days. Status: unknown.
02
Drugs
glycopyrronium
03
Conditions
sialorrhea
Beyond the preview
Go deeper on NCT04873115.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04873115.